No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic

Rheumatology (Oxford). 2020 Sep 1;59(9):2644-2646. doi: 10.1093/rheumatology/keaa388.

Authors

Stefano Alivernini^{1

2}, Luca Petricca¹, Simone Perniola¹, Anna Laura Fedele¹, Maria Rita Gigante¹, Annunziata Capacci¹, Annamaria Paglionico¹, Valentina Varriano², Enrico De Lorenzis², Lucia Lanzo², Fabrizio Melpignano², Pietro Rubortone², Giacomo Tanti², Carlo Tur², Dario Bruno², Laura Gigante², Gerlando Natalello², Lucrezia Verardi², Clara Di Mario², Barbara Tolusso¹, Luisa Mirone^{1

2}, Marco Maria Lizzio¹, Angelo Zoli^{1

2}, Giusy Peluso¹, Silvia Laura Bosello¹, Elisa Gremese^{1

2}

Affiliations

¹ Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS.
² Institute of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy.

No abstract available

Publication types

Letter

MeSH terms

Betacoronavirus*
Biological Products / adverse effects*
COVID-19
Coronavirus Infections / chemically induced
Coronavirus Infections / physiopathology*
Humans
Immunosuppressive Agents / adverse effects*
Italy
Pandemics
Pneumonia, Viral / chemically induced
Pneumonia, Viral / physiopathology*
Receptors, Interleukin-6 / antagonists & inhibitors
Respiration Disorders / chemically induced
Respiration Disorders / virology*
Rheumatic Diseases / drug therapy*
Risk Factors
SARS-CoV-2

Substances

Biological Products
IL6R protein, human
Immunosuppressive Agents
Receptors, Interleukin-6